Niels W.C.J. van de Donk
Dutch Cancer Society(NL)Amsterdam Neuroscience(NL)Amsterdam University Medical Centers(NL)Amsterdam University Medical Centers(NL)Cancer Center Amsterdam(NL)Cancer Center AmsterdamVrije Universiteit Amsterdam(NL)University of Amsterdam(NL)Amsterdam UMC Location Vrije Universiteit Amsterdam(NL)Amsterdam UMC Location VUmc(NL)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research, Peptidase Inhibition and Analysis, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma(2015)1,106 cited
- → Teclistamab in Relapsed or Refractory Multiple Myeloma(2022)1,022 cited
- → Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study(2019)936 cited
- → Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group(2016)914 cited
- → Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma(2016)900 cited
- → Multiple myeloma(2021)815 cited